Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Correlation between SGOL2 expression and clinicopathological characteristics in Cohort 1

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Differential expression of SGOL2 in liver cancer and adjacent tissues

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Quantitative Proteomics, Expressing

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Correlation between SGOL2 expression and clinicopathological characteristics in Cohort 1/2

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: High expression of SGOL2 in HCC. A SGOL2 was overexpressed in HCC in Wurmbach liver database. B Protein expression of SGOL2 was elevated in HCC patients in HPA database. C Immunoblot analysis of SGOL2 in HCC samples and paracancerous tissues from patients in cohort 2, and GAPDH was used as a loading control. D - F SGOL2 staining of paired clinical specimens, and the statistic quantification results in cohorts 1 and 2( n = 202). Protein expression of SGOL2 in the poorly differentiated group was significantly higher than that in the well-differentiated group of cohort 2. G TCGA dataset analysis of the relationship between the SGOL2 expression levels and the prognosis of HCC patients ( n = 364). H Overall survival (OS) analysis of HCC patients with high SGOL2 expression or low SGOL2 expression in cohort 1 ( n = 100). I - J Identification of the optimal penalization coefficient lambda (λ) in the Lasso model in cohort 1. K The nomogram based on SGOL2 for predicting the prognosis of HCC patients in cohort 1. L ROC curve analysis was used to evaluate the performance of this nomogram for 3-year overall survival prediction in the training and validation groups. OS, overall survival; RFS, relapse-free survival; PFS, progression-free survival; DSS, disease-specific survival; HR, hazard ratio. The results are presented as the mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing, Western Blot, Control, Staining, Biomarker Discovery

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Downregulation of SGOL2 expression inhibited the malignant behaviors of HCC cells in vitro. A The mRNA level of SGOL2 in liver and HCC cell lines. B - C , SK-HEP-1, and HEP3B cells were transfected with shNC or shSGOL2 lentivirus, and the knockdown of SGOL2 at the mRNA and protein levels was validated by RT–PCR and Western blots, respectively. GAPDH was used as a loading control. D - G Invasion, migration, sphere formation, and colony formation assays of the SGOL2-downregulated HCC cells were detected and analyzed. H - I Downregulation of SGOL2 expression induced cell cycle arrest in the G1/S phase and activated the apoptosis of HCC cells. J SK-HEP-1, and HEP3B cells were transfected with shNC or shSGOL2, and the proliferation of HCC cells was detected at Days 0, 1, 2, and 3 by CCK-8 assays. K Effect of SGOL2 on the EMT in HCC cell lines. SK-HEP-1 and HEP3B cells were transfected with shNC or shSGOL2, and Western blots were used to detect the levels of E-cadherin, N-cadherin, β-catenin, Vimentin, fibronectin, and MMP9. The results are presented as the mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing, In Vitro, Transfection, Knockdown, Reverse Transcription Polymerase Chain Reaction, Western Blot, Control, Migration, CCK-8 Assay

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: SGOL2 dysregulated the cell cycle by regulating MAD2 in HCC cells. A SK-HEP-1 and HEP3B cells were transfected with shNC or shSGOL2, and the levels of PCNA, cyclin D1, cyclin E1, SGOL2, and MAD2 were detected by Western blots to study the effect of SGOL2 on cell cycle and MAD2. GAPDH was used as a loading control. B SK-HEP-1, and HEP3B cells were transfected with SGOL2 plasmid or vector control plasmid, and the levels of PCNA, cyclin D1, cyclin E1, SGOL2, and MAD2 were detected by Western blots. GAPDH was used as a loading control. C - D , Invasion and sphere formation of SGOL2-upregulated HCC cells with or without M2I-1 treatment were detected and analyzed. The results are presented as the mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Transfection, Western Blot, Control, Plasmid Preparation

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Overexpression of MAD2 reversed the knockdown effects of SGOL2-shRNA in HCC. A - D , F Invasion, migration, sphere formation, and colony formation assays of SGOL2 knockdown HCC cells with or without MAD2 overexpression were performed. E SK-HEP-1, and HEP3B cells were transfected with shSGOL2 or MAD2 plasmid, and the proliferation of HCC cells was detected at Days 3 by CCK-8 assays. The results are presented as the mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Over Expression, Knockdown, shRNA, Migration, Transfection, Plasmid Preparation, CCK-8 Assay

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: SGOL2 exerted its effect by forming a SGOL2-MAD2 complex. A SK-HEP-1 and HEP3B cells were transfected with shSGOL2 lentivirus or SGOL2 plasmid. The colocalization between SGOL2 (Red) and MAD2 (Green) was visualized as yellow fluorescence in the merged panel by Confocal microscopy. B The endogenous interaction between SGOL2 and MAD2 was detected by IP assays in HCC cells

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Transfection, Plasmid Preparation, Fluorescence, Confocal Microscopy

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Upregulated MAD2 expression predicted poor prognosis in HCC and hub gene analysis positively related to both SGOL2 and MAD2. A MAD2 mRNA level is higher in HCC tissues than that in normal liver tissues (UALCAN). B MAD2 has a positive relation with SGOL2 in HCC (GEPIA). C Highly expressed MAD2 predicted poor prognosis in HCC. D Forty-seven genes positively correlated with both SGOL2 and MAD2, as shown by Venn diagram analysis. E The interaction network of the 47 genes. F KEGG enrichment of the 47 genes. G The graph shows the interaction network of the top 15 hub genes. H - I GO analysis and KEGG enrichment of the top 15 hub genes. HR: hazard ratio. J The role and mechanism of SGOL2 in HCC cells. SGOL2 forms a SGOL2-MAD2 complex and further regulates MAD2, resulting in dysregulation of the cell cycle and finally enhancing HCC malignant behaviors

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: SGOL2 knockdown inhibited HCC growth and metastasis in vivo. A - B Xenograft model was set up to study the effects of SGOL2 on HCC tumor growth in vivo. Mice were divided into two groups and inoculated with SK-HEP-1 shNC or SK-HEP-1 shSGOL2 cells (s.c. n = 3, i.v. n = 7). Images of the isolated livers and tumors from sacrificed mice are presented, and the hepatic replacement area (HRA%) and the tumor volumes and tumor weights of the indicated groups were analyzed and compared. Loss of SGOL2 in SK-HEP-1 cells contributed to the reduction in tumorigenesis. C - D , HE staining of metastatic tumors in liver and lung tissues. Representative images and quantitative analysis results are shown

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Knockdown, In Vivo, Isolation, Staining

Journal: Biomarker Research

Article Title: SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

doi: 10.1186/s40364-022-00422-z

Figure Lengend Snippet: Downregulation of SGOL2 expression promoted apoptosis in vivo. A - B IHC staining of CD34, Ki-67, PCNA, and EMT-related markers. Representative images and quantitative analysis results are shown. C The apoptotic area was dramatically increased in the shSGOL2 group compared with the shNC group. The results are presented as the mean ± SD, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001

Article Snippet: The following antibodies were used: SGOL2 antibody (Bethyl, A301–262A, for WB/Co-IP), MAD2 antibody (Bethyl, A300-301A, for WB/Co-IP), SGOL1 (Immunoway, YT4275), cyclin D1 antibody (CST, 55506), cyclin E1 antibody (CST, 20808), PCNA antibody (CST, 13110), normal rabbit IgG (CST, 2729), E-cadherin antibody (CST, 14472), N-cadherin antibody (CST, 13116), vimentin antibody (CST, 5741), MMP9 antibody (CST,13667), β-catenin antibody (CST, 8480), and fibronectin antibody (Abcam, ab268021), secondary antibody (CST,7074/7076), GAPDH antibody (CST, 5174).

Techniques: Expressing, In Vivo, Immunohistochemistry

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 increases the risk of poor prognosis for LUAD. (A, E, and H) Based on the TCGA database, SGO2 expression, ROC curve, and survival analysis in LUAD. (B, F, and I) Based on the GEO database, the validation dataset GSE30219 was used to verify the SGO2 expression, ROC curve, and survival analysis in LUAD. (C) The expression of SGO2 in LUAD and normal tissue. (D) The protein expression of SGO2 in LUAD and normal tissue. (G and J) Immunohistochemical staining of SGO2 in LUAD and normal tissue.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Biomarker Discovery, Immunohistochemical staining, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 is associated with a higher TNM stage of LUAD. (A) Based on the TCGA and GSE30219, the expression of SGO2 in T1 vs T2. (B) Based on the TCGA and GSE30219, the expression of SGO2 in N0 vs N1. (C) Based on the TCGA and GSE31210, the expression of SGO2 in stage I vs stage II + III. (D and G) Based on IHC, the protein expression and staining of SGO2 in T1 vs T2. (E and H) Based on IHC, the protein expression and staining of SGO2 in N0 vs N1. (F and I) Based on IHC, the protein expression and staining of SGO2 in stage I vs stage II + III.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Staining

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 silencing inhibits the proliferation of lung cancer cells. (A)SGO2 expression after knockdown in A549 and H1299. (B)CCK8 assays were performed to detect A549 and H1299 proliferation. (C)Edu assays were performed to detect A549 and H1299 proliferation.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing, Knockdown

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: The downregulation of SGO2 affects migration, invasion, and EMT. (A) A Transwell assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (C) A wound healing assay was performed to examine the effect of SGO2 knockdown on A549 and H1299 cells. (B and D) WB assay the expression levels of E-cadherin, N-cadherin, Vimentin, and Cytokeratin in A549 and H1299 to evaluate the effect on EMT after SGO2 knockdown.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Migration, Transwell Assay, Knockdown, Wound Healing Assay, Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: SGO2 expression and tumor immune infiltration. (A) the expression of SGO2 was positively correlated with the infiltration of Memory B cells, Activated CD4+ memory T cells, and CD8+ T cells, while the infiltration of Memory B cells and Tregs decreased with increasing SGO2 expression. (B) Correlation of SGO2 expression with 28 distinct types of tumor-infiltrating immune cells based on ssGSEA.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High SGO2 predicted poor prognosis and high therapeutic value of lung adenocarcinoma and promoted cell proliferation, migration, invasion, and epithelial-to-mesenchymal transformation

doi: 10.7150/jca.86285

Figure Lengend Snippet: High SGO2 has multiple therapeutic benefits. (A) Comparison of mutational landscapes of SGO between high cluster and low cluster, and Comparison of tumor mutation burden (TMB) between two clusters. (B) Comparison of first-line chemotherapy and targeted therapy drug targets of high and low SGO2 clusters. (C) Comparison of immunomodulatory drug targets of high and low SGO2 clusters.

Article Snippet: The sections were incubated with a 1:1000 rabbit anti-human SGO2 antibody (Cat. # NBP1-83567; Novus, USA) overnight at a 4 °C in wet box.

Techniques: Comparison, Mutagenesis

Journal: Reproductive Medicine and Biology

Article Title: Effects of post‐ovulatory aging on centromeric cohesin protection in murine MII oocytes

doi: 10.1002/rmb2.12433

Figure Lengend Snippet: Comparison of SGO2 expression in mouse oocytes. A, Localization of SGO2 in mouse oocytes. Immunofluorescent staining of SGO2 (green) in the 12‐h aged and fresh oocytes. DNA (blue) was stained with Hoechst 33258. D‐PBS was used as the negative control instead of the primary antibody. Scale bar = 10 μm. B, Comparison of brightness values of SGO2 signal in the 12‐h aged and fresh oocytes. C, Relative expression of SGO2 to α‐tubulin. Bars with different superscripts indicate significant differences ( p < 0.05). D, Western blotting for SGO2 protein in MII oocyte. α‐tubulin was used as a loading control

Article Snippet: The oocyte lysates were diluted with an equal volume of 2× Laemmli sample buffer (Bio‐Rad) containing 5% 2‐mercaptoethanol (Wako) and heated to 100°C for 5 min. Proteins were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE) with a stacking gel containing 4% acrylamide (Wako) and a separating gel containing 7.5–10% acrylamide run for 50 min at 200 V. Proteins were then electrophoretically transferred onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare) for 30 min at 15 V. Each membrane was blocked with PVDF blocking reagent (TOYOBO Co., Ltd.) for 1 h at room temperature, followed by incubation overnight at 4 °C with rabbit anti‐p‐REC8 antibody (1:1,000 dilution, LS‐C47114; LifeSpan Biosciences, Inc.), mouse anti‐PP2A‐Aα/β antibody (1:1,000 dilution; Santa Cruz), rabbit anti‐SGO2 antibody (1:1,000 dilution; My BioSource), mouse anti‐BUB1 antibody (1:500 dilution; Santa Cruz), mouse anti‐ARK‐2 antibody (1:500 dilution; Santa Cruz), or goat anti‐MAD2 antibody (1:500 dilution; Santa Cruz) as the primary antibody.

Techniques: Expressing, Staining, Negative Control, Western Blot

Journal: Frontiers in Oncology

Article Title: The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)

doi: 10.3389/fonc.2019.00429

Figure Lengend Snippet: RNA-Seq gene expression of meiCT genes (A) STRA8 , (B) STAG3 , (C) SGO2 , (D) SYCP3 , and (E) DMC1 in Sézary Syndrome patients compared to normal/control subjects based on pooled data from Choi et al. and Ungewickell et al. datasets. Data was normalized to a mean TPM value for each cohort. Asterisks indicate statistical significance.

Article Snippet: Immunohistochemistry staining was performed on FFPE tissue sections using the Leica BondTM system and the standard protocol F. Sectioned slides were stained with the following anti-human antibodies: rabbit anti- STRA8 (Novus Biologicals), rabbit anti- STAG3 (Proteintech), rabbit anti- DMC1 (Proteintech), rabbit anti- SGO2 (Novus Biologicals), and rabbit anti- SYCP3 (Abcam) using either heat mediated antigen retrieval with sodium citrate buffer (pH 6, epitope retrieval solution 1 ER1) for 20 min or with an EDTA buffer (pH 9, epitope retrieval solution 2 ER2) for 20 min.

Techniques: RNA Sequencing, Gene Expression, Control

Journal: Frontiers in Oncology

Article Title: The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)

doi: 10.3389/fonc.2019.00429

Figure Lengend Snippet: RNA-sequencing results for differentially expressed meiCT genes in two pooled independent cohorts of Sézary Syndrome patients ( 12 , 16 ).

Article Snippet: Immunohistochemistry staining was performed on FFPE tissue sections using the Leica BondTM system and the standard protocol F. Sectioned slides were stained with the following anti-human antibodies: rabbit anti- STRA8 (Novus Biologicals), rabbit anti- STAG3 (Proteintech), rabbit anti- DMC1 (Proteintech), rabbit anti- SGO2 (Novus Biologicals), and rabbit anti- SYCP3 (Abcam) using either heat mediated antigen retrieval with sodium citrate buffer (pH 6, epitope retrieval solution 1 ER1) for 20 min or with an EDTA buffer (pH 9, epitope retrieval solution 2 ER2) for 20 min.

Techniques:

Journal: Frontiers in Oncology

Article Title: The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)

doi: 10.3389/fonc.2019.00429

Figure Lengend Snippet: Results of MeiCT gene expression in lesional skin biopsy samples of patients with CTCL.

Article Snippet: Immunohistochemistry staining was performed on FFPE tissue sections using the Leica BondTM system and the standard protocol F. Sectioned slides were stained with the following anti-human antibodies: rabbit anti- STRA8 (Novus Biologicals), rabbit anti- STAG3 (Proteintech), rabbit anti- DMC1 (Proteintech), rabbit anti- SGO2 (Novus Biologicals), and rabbit anti- SYCP3 (Abcam) using either heat mediated antigen retrieval with sodium citrate buffer (pH 6, epitope retrieval solution 1 ER1) for 20 min or with an EDTA buffer (pH 9, epitope retrieval solution 2 ER2) for 20 min.

Techniques: Gene Expression, Expressing, Staining

Journal: Frontiers in Oncology

Article Title: The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)

doi: 10.3389/fonc.2019.00429

Figure Lengend Snippet: Immunohistochemistry staining of SGO2 in (A) normal human testis (positive control), (B) normal skin (C) stage IIA MF lesional skin, (D) CD8 + MF lesional skin, (E) Sézary Syndrome ( F) peripheral T-Cell Lymphoma. Scale bars are 50 μm. Nuclear staining in malignant lymphocytes is highlighted (red arrow).

Article Snippet: Immunohistochemistry staining was performed on FFPE tissue sections using the Leica BondTM system and the standard protocol F. Sectioned slides were stained with the following anti-human antibodies: rabbit anti- STRA8 (Novus Biologicals), rabbit anti- STAG3 (Proteintech), rabbit anti- DMC1 (Proteintech), rabbit anti- SGO2 (Novus Biologicals), and rabbit anti- SYCP3 (Abcam) using either heat mediated antigen retrieval with sodium citrate buffer (pH 6, epitope retrieval solution 1 ER1) for 20 min or with an EDTA buffer (pH 9, epitope retrieval solution 2 ER2) for 20 min.

Techniques: Immunohistochemistry, Staining, Positive Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Pan-Cancer Analysis of SGO2 Expression ( A ) SGO2 expression profiles across pan-cancers were analyzed using data from the TCGA database. Tumor samples (represented as red boxes) were compared against normal samples (represented as blue boxes) via the Mann-Whitney U test to assess expression differences. ( B ) SGO2 expression patterns across pan-cancers were interrogated utilizing the GEPIA web platform. Tumor samples (depicted as red dots) were contrasted with normal samples (depicted as green dots), with statistical testing following GEPIA’s default analytical pipeline (*p < 0.05, **p < 0.01,***p < 0.001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, MANN-WHITNEY

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Investigation of SGO2 Expression in LUAD. ( A ) Paired comparison: SGO2 expression in tumor vs. matched adjacent normal tissues from LUAD patients (paired t-test). ( B ) Unpaired comparison: SGO2 expression in tumor vs. normal tissues (unpaired t-test). ( C ) Immunohistochemical validation: Immunohistochemical analysis assessed SGO2 expression in LUAD tumor tissues and adjacent peri-tumor tissues from 21 patients (n = 21). Comparison of relative SGO2 expression levels (top) and positive staining area percentages (bottom) between tumor and peri-tumor tissues used paired t-test. ( D ) Clinical stage-related analysis: Based on the TCGA database, SGO2 expression was analyzed across subgroups of T stage, N stage, M stage, and pathological stage. Statistical method: One-way ANOVA with Bonferroni post-hoc test. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Comparison, Immunohistochemical staining, Biomarker Discovery, Staining

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Elevated SGO2 expression was associated with poor prognosis in LUAD patients. ( A-C ) Kaplan-Meier survival analyses (via log-rank test) from TCGA database comparing LUAD patients with high vs. low SGO2 expression (stratified by median). ( A ) OS: High-expression group (n = 265) showed significantly worse prognosis than low-expression group (n = 265) (HR = 1.64, p < 0.001). ( B ) DSS: High-expression group (n = 247) had poorer outcomes than low-expression group (n = 248) (HR = 1.87, p < 0.001). ( C ) PFS: High-expression group (n = 265) exhibited shorter PFS than low-expression group (n = 265) (HR = 1.47, p = 0.005). ( D-E ) Validation in GEO datasets (log-rank test): ( D ) GSE13213 : High-expression group (n = 75) had significantly reduced survival vs. low-expression group (n = 42) (p < 0.01). ( E ) GSE31210 : High-expression group (n=84) showed worse prognosis compared to low-expression group (n = 120) (p = 0.005). HR: Hazard ratio.

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Biomarker Discovery

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: The diagnostic ROC curve for SGO2. ( A ) Receiver operating characteristic (ROC) curve evaluating SGO2 expression as a diagnostic biomarker for LUAD. The area under the curve (AUC) was 0.873 (95% CI: 0.843-0.903), indicating high discriminatory power.

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Diagnostic Assay, Expressing, Biomarker Discovery

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 expression in LUAD cell lines relative to normal Beas-2B cells. ( A ) Combined subpanels showing relative SGO2 mRNA expression: ( a-c ) Relative SGO2 mRNA expression in A549 ( a ), H1975( b ) and H1299 ( c ) cells, normalized to Beas-2B. (n = 3, Student’s t-test). ( B-C ) Representative western blot ( B ) and quantitative analysis ( C ) of SGO2 protein expression in the same cell lines. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as the loading control (n = 3, one-way ANOVA with Tukey’s post hoc test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Expressing, Western Blot, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 knockdown suppressed malignant behaviors in LUAD cells. ( A-B ) Validation of siRNA-mediated SGO2 knockdown efficiency by ( A ) qPCR and ( B ) Western blot. (n = 3, one-way ANOVA with Tukey’s post hoc test). ( C-E ) Proliferation (CCK-8), migration (wound healing), and invasion (Matrigel) assays in SGO2-depleted H1299 cells. (n = 3, Student’s t-test). ( F ) Western blot analysis of EMT markers (N-cadherin, E-cadherin, Vimentin) in SGO2-knockdown H1299 cells with \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as loading control. (n = 3, Student’s t-test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Knockdown, Biomarker Discovery, Western Blot, CCK-8 Assay, Migration, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: Knockdown of SGO2 affected the cell cycle in LUAD cells. ( A ) Flow cytometry analysis of cell cycle distribution (G1, S, G2/M phases) in si-SGO2 and si-NC groups. (n = 3, two-way ANOVA with Sidak’s test). ( B ) Western blot of cell cycle proteins (Cyclin B1, Cyclin D1). \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\beta$$\end{document} -actin served as control (n = 3, Student’s t-test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Knockdown, Flow Cytometry, Western Blot, Control

Journal: Scientific Reports

Article Title: Elevated SGO2 expression in lung adenocarcinoma promotes migration and invasion via MAD2 and correlates with poor prognosis

doi: 10.1038/s41598-025-10993-0

Figure Lengend Snippet: SGO2 regulated LUAD cell migration and invasion via MAD2. ( A ) GO and KEGG enrichment analysis of genes associated with SGO2. (The use permission from Kanehisa Laboratories has been obtained.) ( B ) Correlation analysis between SGO2 and MAD2 expression (Pearson’s R = 0.62, p < 0.001). ( C-D ) Verification of SGO2 overexpression efficiency using qPCR and Western blot, and analysis of MAD2 expression following SGO2 knockdown or overexpression (n = 3, Student’s t-test). ( E ) Invasion and migration assays of H1299 cells in three groups: SGO2 overexpression (OE-SGO2), control (OE-SGO2-NC), and SGO2-OE with MAD2 inhibitor (OE-M2I-1) (n = 3, one-way ANOVA with Tukey’s post hoc test). Original blots are shown in Fig. . (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

Article Snippet: SGO2 antibody , 1:1000 , A08632 , Boster.

Techniques: Migration, Expressing, Over Expression, Western Blot, Knockdown, Control

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: The expression level of SGO2 is related to pathological grading of gliomas. The SGO2 mRNA level in different grade of gliomas and non-tumor brain tissue from GEO profile (GDS1962/230165_at/SGO2) ( a ), TCGA ( b ), and CCGA ( c ). SGO2 expression was significantly higher in high-grade gliomas (Grade III and IV) than in low-grade gliomas (Grade II) and non-tumor control. The Y-axis indicates the SGO2 mRNA expression. The p value was adjusted by Bonferroni method in R software (version 3.0.1) between each group.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Expressing, Control, Software

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: The expression level of SGO2 is related to the survival of patients with high-grade gliomas. The Kaplan–Meier survival curve analyzed from GEO profile (GDS1816/230165_at/SGO2) ( a ), TCGA ( b ), and CGGA ( c ). Data showed that patients with high expression of SGO2 had unfavorable survival outcome. (GDS1816/230165_at/SGO2, n = 77, p = 0.0011 by log-rank test, 95% CI 1.000–1.00, hazard ratio 1.001; TCGA, n = 343, p < 1 × 10 –15 by log-rank test, 95% CI 0.87–5.30, hazard ratio 3.90; CGGA, n = 209, p = 1.23 × 10 –11 by log-rank test, 95% CI 2.13–4.25, hazard ratio 3.01).

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Expressing

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: Validation of SGO2 mRNA and protein levels in glioma cell lines and normal brain tissue ( a ) qRT-PCR was performed to examine SGO2 mRNA expression and the quantitative results are shown in glioma cell lines. The relative expressions were normalized with normal brain. Bars mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.005 showed significant differences. Data are representative of three independent experiments. ( b ) Protein lysates of glioma cell lines, including U87MG, LN229, GBM8401, and U118MG were applied to SDS-PAGE and Western blot analysis to quantitate SGO2 protein expression (full length blot is presented in Supplementary Fig. ). GAPDH served as a loading control.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Biomarker Discovery, Quantitative RT-PCR, Expressing, SDS Page, Western Blot, Control

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: Validation of SGO2 protein expression in human gliomas and non-tumor brain tissue. Hematoxylin and eosin staining of non-tumor brain tissue ( a ), low grade ( b ) and high grade gliomas ( c ). The immunohistochemical staining of SGO2 on non-tumor brain tissue ( d ), low grade ( e ), and high grade gliomas ( f ) (scale bar: 50 μm). ( g – i ) The SGO2 immunostaining scores in normal brain tissue, low-grade glioma and high-grade glioma were statistically analyzed. The adjusted p value was calibrated between each group.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Biomarker Discovery, Expressing, Staining, Immunohistochemical staining, Immunostaining

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: The effect of SGO2 on cell proliferation and apoptosis ( a ) The SGO2 knockdown model constructed by siRNA 25 nM transfection into LN229 and GBM8401 cell lines. The knockdown efficiency of SGO2 siRNA or control siRNA in infected LN229 and GBM8401 cells measured by RT-qPCR. Bars, mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.005 showed significant differences. Data are representative of three independent experiments. ( b ) LN229 and GBM8401 cells were transfected with 25 nM siRNA or siControl. Cell count was determined at the indicated time points. The data are expressed as the mean ± s.d.; n = 3; ** p < 0.01, and *** p < 0.001. ( c ) LN229 and GBM8401 cell with si SGO2 or siControl transfection were labeled with BrdU then proceeded analysis by flow cytometry (** p < 0.01, *** p < 0.005). ( d ) Cell cycle analysis of LN229 and GBM8401 si SGO2 cells was determined by propidium iodide (PI) stain and flow cytometry. The data are expressed as the mean ± s.d.; n = 3; * p < 0.05, ** p < 0.01. ( e ) Cell apoptosis analysis of LN 229 and GBM8401 si SGO2 cells were determined by tetraethylbenzimidazolylcarbocyanine iodide (JC-1) dye and flow cytometry.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Knockdown, Construct, Transfection, Control, Infection, Quantitative RT-PCR, Cell Counting, Labeling, Flow Cytometry, Cell Cycle Assay, Staining

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: The effect of SGO2 knockdown on cell migration detected by wound-healing assays. Images and Quantitative analysis of LN229 ( a ) and GBM8401 ( b ) cells in the wound-healing assay. Data are presented as the mean ± SD (n = 3). * p < 0.05, ** p < 0.01.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: Knockdown, Migration, Wound Healing Assay

Journal: Scientific Reports

Article Title: Shugoshin 2 is a biomarker for pathological grading and survival prediction in patients with gliomas

doi: 10.1038/s41598-021-97119-4

Figure Lengend Snippet: The SGO2 protein–protein interaction (PPI) network. ( a ) In the PPI network established by STRING dataset, SGO2 is a hub protein. ( b ) The STRING dataset also predicted the association between SGO2, ARUKB, and FOXM1. ( c ) Protein lysates of LN229 and GBM8401 were applied to SDS-PAGE and Western blot to investigate the protein expression of AURKB and FOXM1(full length blot is presented in Supplementary Fig. ). α-actinin served as a loading control.

Article Snippet: Anti-SGO2 antibody (Atlas Antibodies AB, Stockholm.

Techniques: SDS Page, Western Blot, Expressing, Control